Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.

@article{Tamayo2015CharacterizingMB,
  title={Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.},
  author={Sally G Tamayo and William Frank Peacock and Manesh R. Patel and Nicholas M. Sicignano and Kathleen Pillsbury Hopf and Larry E Fields and Troy C. Sarich and Shujian Wu and Daniel Yannicelli and Zhong Yuan},
  journal={Clinical cardiology},
  year={2015},
  volume={38 2},
  pages={63-8}
}
BACKGROUND In nonvalvular atrial fibrillation (NVAF), rivaroxaban is used to prevent stroke and systemic embolism. OBJECTIVE To evaluate major bleeding (MB) in NVAF patients treated with rivaroxaban in a real-world clinical setting. METHODS From January 1, 2013, to March 31, 2014, US Department of Defense electronic health care records were queried to describe MB rates and demographics. Major bleeding was identified using a validated algorithm. RESULTS Of 27 467 patients receiving… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS
50 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…